Urinary incontinence—pharmacotherapy options

References

• Haylen BT, de Ridder D, Freeman RM, . International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, . The standardisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, . The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54:543–62.
   PubMed Web of Science ®Google Scholar
• Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004; 63(Suppl 3A):32–41.
   PubMedGoogle Scholar
• Andersson KE, Chapple CR, Cardozo L, . Pharmacological treatment of urinary incontinence. Abrams P, Cardozo L, Khoury S, Wein AJ. Incontinence. 4th. Paris: Health Publication Ltd; 2009. 631–700.
   Google Scholar
• Fenner DE, Trowbridge ER, Patel DA, . Establishing the prevalence of incontinence study: racial differences in women's patterns of urinary incontinence. J Urol. 2008; 179:1455–60.
   PubMed Web of Science ®Google Scholar
• Milsom I, Altman D, Lapitan MC, Nelson R, Sillen U, Thom D. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). Abrams P, Cardozo L, Khoury S, Wein AJ. Incontinence. 4th. Paris: Health Publications Ltd; 2009. 37–111.
   Google Scholar
• Koelbl H, Nitti V, Baessler K, Salvatore S, Sultan A, Yamaguchi O. Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse. Abrams P, Cardozo L, Khoury S, Wein AJ. Incontinence. 4th. Paris: Health Publication Ltd; 2009. 255–330.
   Google Scholar
• Nitti VW, Combs AJ. Correlation of Valsalva leak point pressure with subjective degree of stress urinary incontinence in women. J Urol. 1996;155:281–5.
   PubMed Web of Science ®Google Scholar
• Blaivas JG, Olsson CA. Stress incontinence: classification and surgical approach. J Urol. 1988;139:727–31.
   PubMed Web of Science ®Google Scholar
• Wein AJ. Pathophysiology and classification of voiding dysfunction. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell–Walsh Urology. 9th. Philadelphia: Saunders; 2007. 1973–85.
   Google Scholar
• DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol. 1994;170:1713–20.
   PubMed Web of Science ®Google Scholar
• Wein AJ. Neuromuscular dysfunction of the lower urinary tract. Walsh PC, Retik AB, Stamey TA, Vaughan ED. Campbell's Urology. 6th. Philadelphia: Saunders; 1992. 573–642.
   Google Scholar
• Wein AJ, Levin RM, Barrett DM. Voiding function: relevant anatomy, physiology, and pharmacology. Duckett JW, Howards ST, Grayhack JT, Gillenwater JY. Adult and Pediatric Urology. St Louis: Mosby; 1991. 933–99.
   Google Scholar
• Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993: 253–308.
   PubMedGoogle Scholar
• Anderson KE, Wein AJ. Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631.
   PubMedGoogle Scholar
• Jensen D Jr. Pharmacological studies of the uninhibited neurogenic bladder. Acta Neurol Scand. 1981;64:175–80.
   PubMedGoogle Scholar
• Anderson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol. 2003;43:1–5.
   PubMed Web of Science ®Google Scholar
• Chess-Williams R. Muscarinic receptors of the urinary bladder: Detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002;22:133–45.
   PubMedGoogle Scholar
• Yoshida M, Miyamae K, Iwashita H, . Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63(Suppl 1):17–23.
   PubMedGoogle Scholar
• Andersson KE, Wein AJ. Pharmacologic management of storage and emptying failure. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell–Walsh Urology. 9th. Philadelphia: Saunders; 2007. 2091–123.
   Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100:987–1006.
   PubMed Web of Science ®Google Scholar
• Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42: 1243–85.
   PubMed Web of Science ®Google Scholar
• Witte LP, Mulder WM, de la Rosette JJ, . Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol. 2009;19:13–19.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1998;104:988–93.
   Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55(5A Suppl): 47–9, discussion 50.
   PubMedGoogle Scholar
• Pesce F, Rubilotta E, D'Amica A, . Long-term anticholinergic therapy: duration and causes of discontinuation. Paris, France: International Continence Society; 2003.
   Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.
   PubMed Web of Science ®Google Scholar
• Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 1997;157: 1093–7.
   PubMed Web of Science ®Google Scholar
• Thüroff JW, Chartier E, Corcus J, . Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16(Suppl 1):S48–61.
   Google Scholar
• Baigrie RJ, Kelleher JP, Fawcett KP, . Oxybutynin: is it safe? Br J Urol. 1988;62:319.
   PubMedGoogle Scholar
• Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999; 39:289–96.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Appell RA, Sathyan G, . A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartate. Clin Ther. 2001;23:753.
   PubMedGoogle Scholar
• Anderson R, Mobley D, Blank B, . Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol. 1999;161:1809–12.
   PubMed Web of Science ®Google Scholar
• Corcos J, Casey R, Patrick A, . Uromax Study Group. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int. 2006;97:520–7.
   PubMedGoogle Scholar
• Dmochowski RR, Davila GW, Sinner NR, . Efficacy and safely of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580–6.
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multi-center, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:150–1.
   PubMedGoogle Scholar
• Dmochowski RR, Davila GW, Sinner NR, . Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003; 62:237–42.
   PubMed Web of Science ®Google Scholar
• Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51:907–14.
   PubMed Web of Science ®Google Scholar
• Connor JP, Betrus G, Fleming P, . Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. J Urol. 1994;151:1045–7.
   PubMedGoogle Scholar
• Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord. 1996;34:284–7.
   PubMedGoogle Scholar
• Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia. 1991;29:84–90.
   PubMedGoogle Scholar
• Staskin DR, Dmochowski RR, Sand PK, . Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181:1764–72.
   PubMed Web of Science ®Google Scholar
• Brynne N, Stahl MMS, Hallen B, . Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35:287.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Sundquist S, Gillberg PG. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn. 1996;15:310–11.
   Google Scholar
• van Kerrebroeck P, Kreder K, Jonas U, . Tolterodine once daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414–21.
   PubMed Web of Science ®Google Scholar
• Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998; 55:813.
   PubMed Web of Science ®Google Scholar
• Xie HG, Kim RB, Wood AJ, . Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.
   PubMed Web of Science ®Google Scholar
• Diefenbach K, Jaeger K, Wollny A, . Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med. 2008;9:579–82.
   PubMedGoogle Scholar
• Elinoff V, Bavendam T, Glasser DB, . Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006;60:745–51.
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand P, Dmochowski R, . Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study. Mayo Clin Proc. 2001;76:358–63.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, . OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc. 2003;78: 687–95.
   PubMed Web of Science ®Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177–84.
   PubMed Web of Science ®Google Scholar
• Song C, Park JT, Heo KO, . Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci. 2006;21:1060–3.
   PubMedGoogle Scholar
• Mattiasson A, Blaakaer J, Høye K, . Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54–60.
   PubMed Web of Science ®Google Scholar
• Millard RJ; Asia Pacific Tolterodine Study Group. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn. 2004;23:48–53.
   PubMed Web of Science ®Google Scholar
• Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636–44.
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoshimura N, Masuda H, . Intravesical instillation of human urine after oral administration of trospium, tolterodine, and oxybutynin in a rat model of detrusor overactivity. BJU Int. 2006;97:400.
   PubMed Web of Science ®Google Scholar
• Stöhrer M, Bauer P, Giannetti BM, . Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: A multicenter placebo-controlled double-blind trial. Urol Int. 1991;47: 138–43.
   PubMedGoogle Scholar
• Madersbacher H, Stöhrer M, Richter R, . Trospium chloride versus oxybutynin: A randomized double blind, multicenter trial in the treatment of detrusor hyperreflexia. Br J Urol. 1995;75:452–6.
   PubMedGoogle Scholar
• Allousi S, Laval K-U, Eckert R. Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): A double-blind, randomised, multicentre, placebo-controlled study. J Clin Res. 1998;1:439–51.
   Google Scholar
• Halaska M, Ralph G, Wiedemann A, . Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392–9.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71:449–54.
   PubMed Web of Science ®Google Scholar
• Fröhlich G, Burmeister S, Wiedemann A, Bulitta M. [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]. Arzneimittelforschung. 1998 48:486–91.
   PubMed Web of Science ®Google Scholar
• Walter P, Grosse J, Bihr AM, . Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study. Neurourol Urodyn. 1999;18:447–53.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kobayashi S, Suzuki M, . M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:97–103.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Arano P, Bosch JL, . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93:71–7.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, . Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172(pt 1):1919–24.
   PubMedGoogle Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, . STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR Trial. Eur Urol. 2005;48:464–70.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol. 2002;1:23.
   Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once daily treatment for overactive bladder. Eur Urol. 2004;45: 420–9.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Steers W, Norton P, . A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95:993.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173:493–8.
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, . Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204–12.
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, . Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101: 1036–42.
   PubMed Web of Science ®Google Scholar
• Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–96.
   PubMed Web of Science ®Google Scholar
• Khullar V, Rovner ES, Dmochowski R, . Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839–43.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Tubaro A, Wang JT, . Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102:56–61.
   PubMed Web of Science ®Google Scholar
• Muskat Y, Bukovsky I, Schneider D, Langer R. The use of scopolamine in the treatment of detrusor instability. J Urol. 1996;156:1989–90.
   PubMed Web of Science ®Google Scholar
• Ancelin ML, Artero S, Portet F, . Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006; 332:455–9.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Imamura T, Tanimukai S, . Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet. 2000;356:568.
   PubMed Web of Science ®Google Scholar
• Kato K, Furuhashi K, Suzuki K, . Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14:595–7.
   PubMed Web of Science ®Google Scholar
• Fink AM, Aylward GW. Buscopan and glaucoma: a survey of current practice. Clin Radiol. 1995;50:160–4.
   PubMed Web of Science ®Google Scholar
• Hollister LE. Current antidepressants. Annu Rev Pharmacol Toxicol. 1986;26:23–37.
   PubMed Web of Science ®Google Scholar
• Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014–24.
   PubMed Web of Science ®Google Scholar
• Steers WD, Herschorn S, Kreder KJ. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007;100:337–45.
   PubMed Web of Science ®Google Scholar
• Olubadewo J. The effect of imipramine on rate detrusor muscle contractility. Arch Int Pharmacodyn Ther. 1980; 145:84–94.
   Google Scholar
• Foreman MM, McNulty AM. Alterations in K(+)-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition. Life Sci. 1993;53:193–200.
   PubMedGoogle Scholar
• Castleden CM, George CF, Renwick AG, . Imipramine—a possible alternative to current therapy for urinary incontinence in elderly. J Urol. 1981;125:318–20.
   PubMed Web of Science ®Google Scholar
• Raezer DM, Benson GS, Wein AJ, . The functional approach to the management of the pediatric neuropathic bladder: a clinical study. J Urol. 1977;117:649–54.
   PubMed Web of Science ®Google Scholar
• Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Synder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynaecol. 2001;97:116–20.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynaecol. 2004;103:254–60.
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Cochrane BB, Nygaard IE, . Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935–48.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288: 321–33.
   PubMed Web of Science ®Google Scholar
• Samsioe G, Jansson I, Mellström D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas. 1985;7:335–42.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Rekers H, Tapp A, . Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47–53.
   PubMed Web of Science ®Google Scholar
• Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women—a double-blind placebo-controlled study. J Obstet Gynaecol. 2001;21:383–5.
   PubMedGoogle Scholar
• Eriksen PS, Rasmussen H. Low dose 17 beta oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol. 1992;44:137–44.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83:892–7.
   PubMed Web of Science ®Google Scholar
• Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003; 2:CD001405.
   PubMedGoogle Scholar
• Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006; 85:155–60.
   PubMed Web of Science ®Google Scholar
• Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342:665.
   PubMed Web of Science ®Google Scholar
• Reitz A, Stöhrer M, Kramer G, . European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45: 510–5.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007;99:247–62.
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231–6.
   PubMed Web of Science ®Google Scholar
• Kalsi V, Gonzales G, Popat R, . Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452–7.
   PubMed Web of Science ®Google Scholar
• Reitz A, Denys P, Fermanian C, . Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52:1729–35.
   PubMed Web of Science ®Google Scholar
• Schmid D, Sauermann P, Werner M, . Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85.
   PubMed Web of Science ®Google Scholar
• Duthie J, Wilson DI, Herbison GP. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2007;3:CD005493.
   Google Scholar
• Rashbaum M, Mandelbaum CC. Non-operative treatment of urinary incontinence in women. Am J Obstet Gynecol. 1948;56:777.
   PubMedGoogle Scholar
• Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology. 1975;5:624–5.
   PubMedGoogle Scholar
• Alhasso A, Glazener CMA, Pickard R, . Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005;3:CD001842.
   Google Scholar
• Fraser MO, Chancellor MB. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int. 2003;91:743–8.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Miklos JR, Norton PA, . Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170(4 Pt 1): 1259–63.
   PubMedGoogle Scholar
• Mariappan P, Alhasso A, Ballantyne Z, . Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007;51:67–74.
   PubMed Web of Science ®Google Scholar
• Gilja I, Radej M, Kovacic M, . Conservative treatment of female stress incontinence with imipramine. J Urol. 1984;132:909–11.
   PubMed Web of Science ®Google Scholar
• Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83: 12–18.
   PubMed Web of Science ®Google Scholar
• Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas. 1995;20:129–38.
   Web of Science ®Google Scholar
• Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol. 1996;88:745–9.
   PubMed Web of Science ®Google Scholar
• Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol. 1999;106:711–8.
   PubMedGoogle Scholar
• Al-Badr A, Ross S, Soroka D, Drutz HP. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can. 2003;25:567–74.
   PubMedGoogle Scholar
• Matthiesen TB, Rittig S, Nørgaard JP, . Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol. 1996;156:1292–9.
   PubMed Web of Science ®Google Scholar
• Nørgaard JP, Rittig S, Djurhuus JC. Nocturnal enuresis: an approach to treatment based on pathogenesis. J Pediatr. 1989;114(4 Pt 2):705–10.
   PubMedGoogle Scholar
• Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol. 1996;53:1270–5.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Desmopreesin for the treatment of adult nocturia. Therapy. 2008;5:667–83.
   Google Scholar
• Hashim H, Malmberg L, Graugaard-Jensen C. Desmopressin, as a ‘designer-drug,’ in the treatment of overactive bladder syndrome. Neurourol Urodyn. 2009;28:40–6.
   Google Scholar
• Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn. 2006;25:105–9.
   PubMed Web of Science ®Google Scholar
• Marion, DW. Desmopressin: Drug information. UpToDate, Basow, DS, Waltham, MA, 2011.
   Google Scholar